Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2015
At a glance
- Drugs Faldaprevir (Primary) ; Raltegravir (Primary)
- Indications Hepatitis C; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2013 New trial record